TY - JOUR AU - Tang, J. AU - Shalabi, A. AU - Vm, H. -. L. PY - 2018 DA - 2018// TI - Comprehensive analysis of the clinical immuno-oncology landscape JO - Ann Oncol VL - 29 UR - https://doi.org/10.1093/annonc/mdx755 DO - 10.1093/annonc/mdx755 ID - Tang2018 ER - TY - JOUR AU - Postow, M. A. AU - Sidlow, R. AU - Hellmann, M. D. PY - 2018 DA - 2018// TI - Immune-related adverse events associated with immune checkpoint blockade JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMra1703481 DO - 10.1056/NEJMra1703481 ID - Postow2018 ER - TY - JOUR AU - Meropol, N. J. AU - Schrag, D. AU - Smith, T. J. AU - Mulvey, T. M. AU - Langdon, R. M. AU - Blum, D. PY - 2009 DA - 2009// TI - American society of clinical oncology guidance statement: the cost of cancer care JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2009.23.1183 DO - 10.1200/JCO.2009.23.1183 ID - Meropol2009 ER - TY - JOUR AU - Matter-Walstra, K. AU - Schwenkglenks, M. AU - Aebi, S. AU - Dedes, K. AU - Diebold, J. AU - Pietrini, M. PY - 2016 DA - 2016// TI - A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous nsclc including pd-l1 testing JO - J Thorac Oncol VL - 11 UR - https://doi.org/10.1016/j.jtho.2016.05.032 DO - 10.1016/j.jtho.2016.05.032 ID - Matter-Walstra2016 ER - TY - JOUR AU - Vouk, K. AU - Benter, U. AU - Amonkar, M. M. AU - Marocco, A. AU - Stapelkamp, C. AU - Pfersch, S. PY - 2016 DA - 2016// TI - Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries JO - J Med Econ VL - 19 UR - https://doi.org/10.1080/13696998.2016.1184155 DO - 10.1080/13696998.2016.1184155 ID - Vouk2016 ER - TY - JOUR AU - Tartari, F. AU - Santoni, M. AU - Burattini, L. AU - Mazzanti, P. AU - Onofri, A. AU - Berardi, R. PY - 2016 DA - 2016// TI - Economic sustainability of anti-pd-1 agents nivolumab and pembrolizumab in cancer patients: recent insights and future challenges JO - Cancer Treat Rev VL - 48 UR - https://doi.org/10.1016/j.ctrv.2016.06.002 DO - 10.1016/j.ctrv.2016.06.002 ID - Tartari2016 ER - TY - JOUR AU - Gafni, A. AU - Birch, S. PY - 2006 DA - 2006// TI - Incremental cost-effectiveness ratios (icers): the silence of the lambda JO - Soc Sci Med VL - 62 UR - https://doi.org/10.1016/j.socscimed.2005.10.023 DO - 10.1016/j.socscimed.2005.10.023 ID - Gafni2006 ER - TY - JOUR AU - Khera, N. PY - 2014 DA - 2014// TI - Reporting and grading financial toxicity JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2014.57.8740 DO - 10.1200/JCO.2014.57.8740 ID - Khera2014 ER - TY - JOUR AU - Husereau, D. AU - Drummond, M. AU - Petrou, S. AU - Carswell, C. AU - Moher, D. AU - Greenberg, D. PY - 2013 DA - 2013// TI - Consolidated health economic evaluation reporting standards (cheers) statement JO - BMJ VL - 346 UR - https://doi.org/10.1136/bmj.f1049 DO - 10.1136/bmj.f1049 ID - Husereau2013 ER - TY - JOUR AU - Husereau, D. AU - Drummond, M. AU - Petrou, S. AU - Carswell, C. AU - Moher, D. AU - Greenberg, D. PY - 2013 DA - 2013// TI - Consolidated health economic evaluation reporting standards (cheers)--explanation and elaboration: a report of the ispor health economic evaluation publication guidelines good reporting practices task force JO - Value Health VL - 16 UR - https://doi.org/10.1016/j.jval.2013.02.002 DO - 10.1016/j.jval.2013.02.002 ID - Husereau2013 ER - TY - JOUR AU - Meregaglia, M. AU - Cairns, J. PY - 2015 DA - 2015// TI - Economic evaluations of follow-up strategies for cancer survivors: a systematic review and quality appraisal of the literature JO - Expert Rev Pharmacoecon Outcomes Res VL - 15 UR - https://doi.org/10.1586/14737167.2015.1087316 DO - 10.1586/14737167.2015.1087316 ID - Meregaglia2015 ER - TY - JOUR AU - Edwards, K. AU - Jones, N. AU - Newton, J. AU - Foster, C. AU - Judge, A. AU - Jackson, K. PY - 2017 DA - 2017// TI - The cost-effectiveness of exercise-based cardiac rehabilitation: a systematic review of the characteristics and methodological quality of published literature JO - Health Econ Rev VL - 7 UR - https://doi.org/10.1186/s13561-017-0173-3 DO - 10.1186/s13561-017-0173-3 ID - Edwards2017 ER - TY - JOUR AU - Iannazzo, S. AU - Iliza, A. C. AU - Perrault, L. PY - 2018 DA - 2018// TI - Disease-modifying therapies for multiple sclerosis: a systematic literature review of cost-effectiveness studies JO - Pharmacoeconomics VL - 36 UR - https://doi.org/10.1007/s40273-017-0577-2 DO - 10.1007/s40273-017-0577-2 ID - Iannazzo2018 ER - TY - JOUR AU - Kadour, A. AU - Wa, M. AU - Al-Badriyeh, D. PY - 2018 DA - 2018// TI - Pharmacoeconomics evaluations of oral anticancer agents: systematic review of characteristics, methodological trends, and reporting quality JO - Value Health Reg Issues VL - 16 UR - https://doi.org/10.1016/j.vhri.2018.05.003 DO - 10.1016/j.vhri.2018.05.003 ID - Kadour2018 ER - TY - JOUR AU - Aguiar, P. M. AU - Lima, T. M. AU - Storpirtis, S. PY - 2016 DA - 2016// TI - Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality? JO - J Clin Pharm Ther VL - 41 UR - https://doi.org/10.1111/jcpt.12384 DO - 10.1111/jcpt.12384 ID - Aguiar2016 ER - TY - JOUR AU - Monten, C. AU - Veldeman, L. AU - Verhaeghe, N. AU - Lievens, Y. PY - 2017 DA - 2017// TI - A systematic review of health economic evaluation in adjuvant breast radiotherapy: quality counted by numbers JO - Radiother oncol VL - 125 UR - https://doi.org/10.1016/j.radonc.2017.08.034 DO - 10.1016/j.radonc.2017.08.034 ID - Monten2017 ER - TY - JOUR AU - Shamseer, L. AU - Moher, D. AU - Clarke, M. AU - Ghersi, D. AU - Liberati, A. AU - Petticrew, M. PY - 2015 DA - 2015// TI - Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: elaboration and explanation JO - BMJ VL - 350 UR - https://doi.org/10.1136/bmj.g7647 DO - 10.1136/bmj.g7647 ID - Shamseer2015 ER - TY - JOUR AU - Moher, D. AU - Shamseer, L. AU - Clarke, M. AU - Ghersi, D. AU - Liberati, A. AU - Petticrew, M. PY - 2015 DA - 2015// TI - Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015 statement JO - Syst Rev VL - 4 UR - https://doi.org/10.1186/2046-4053-4-1 DO - 10.1186/2046-4053-4-1 ID - Moher2015 ER - TY - STD TI - Thomas J, Brunton J, Graziosi S. Eppi-reviewer 4.0: software for research synthesis. London: Social science research unit, Institute of education, University of london; 2010. Available from: https://eppi.ioe.ac.uk/cms/default.aspx?tabid=1913. Accessed 31 May 2019. UR - https://eppi.ioe.ac.uk/cms/default.aspx?tabid=1913 ID - ref19 ER - TY - JOUR AU - Moher, D. AU - Liberati, A. AU - Tetzlaff, J. AU - Altman, D. G. PY - 2009 DA - 2009// TI - Preferred reporting items for systematic reviews and meta-analyses: the prisma statement JO - J Clin Epidemiol VL - 62 UR - https://doi.org/10.1016/j.jclinepi.2009.06.005 DO - 10.1016/j.jclinepi.2009.06.005 ID - Moher2009 ER - TY - JOUR AU - Liberati, A. AU - Altman, D. G. AU - Tetzlaff, J. AU - Mulrow, C. AU - Gøtzsche, P. C. AU - JPA, I. PY - 2009 DA - 2009// TI - The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration JO - J Clin Epidemiol VL - 62 UR - https://doi.org/10.1016/j.jclinepi.2009.06.006 DO - 10.1016/j.jclinepi.2009.06.006 ID - Liberati2009 ER -